Aspyra Enhances CyberLAB LIS with Added Data Sharing Capabilities
14 Octubre 2009 - 8:30AM
Business Wire
Aspyra, Inc. (AMEX: APY) today announced the release of
CyberLAB version 7.2.5, for general distribution to existing and
new Laboratory Information System customers.
Aspyra’s CyberLAB LIS system is a scalable, feature-rich, and
proven LIS solution for the hospital, clinic, and reference
laboratory settings. CyberLAB LIS features decision support tools
with auto-verification, automated clinical reporting and multisite
management.
CyberLAB version 7.2.5 includes features that enhance the
organization’s ability to connect and share data with multiple
third party systems. This includes the capture and processing of
incoming orders from more than one host system, such as Electronic
Medical Records (EMR), Hospital Information System (HIS) or
Practice Management System (PMS). By increasing the methods of
order receipt, the laboratory can expand their business, increase
patient sample volume and reduce medical errors with electronic
order placement.
Jason Skolnick, Aspyra’s Director of Sales and Marketing,
stated, “Interoperability and data sharing tools are critical
components for today’s healthcare organizations.” He continued, “By
adding additional features to our LIS for interfacing with EMRs and
other host systems, we enable the laboratory to increase their
community footprint and provide a higher level of patient care with
immediate access to critical patient data.”
Aspyra solutions provide integrated technologies and services
that improve the efficiency, safety and quality of patient care.
Aspyra works directly with customers through its own sales and
service staff as well as through an extensive partner network. The
company currently counts over 440 customers and over 700
application installations in its installed base.
Safe Harbor
Statement
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements related to anticipated revenues,
expenses, earnings, operating cash flows, the outlook for Aspyra’s
markets and the demand for its products. Forward-looking statements
are not guarantees of future performance and are inherently subject
to uncertainties and other factors which could cause actual results
to differ materially from the forward-looking statement. Such
statements are based upon, among other things, assumptions made by,
and information currently available to, management as of today the
date of this press release, including management's own knowledge
and assessment of the Company’s industry and competition. Factors
that could cause Aspyra’s actual results to differ materially from
these forward-looking statements include among others: the
competitive environment; unexpected technical and marketing
difficulties inherent in major product development efforts; the
potential need for changes in our long-term strategy in response to
future developments; future advances in clinical information
technology and procedures, as well as potential changes in
government regulations and healthcare policies; and rapid
technological change in the microelectronics and software
industries. The Company refers interested persons to its most
recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q
and its other SEC filings for a description of additional
uncertainties and factors, which may affect forward-looking
statements. The Company assumes no duty to update its
forward-looking statements.
Aspyra (AMEX:APY)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Aspyra (AMEX:APY)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
